We live in an age of incredible scientific discovery. Scientists can now sequence entire human genomes in just hours. They can turn skin cells into heart cells and can create computer chips that mimic how the brain works. If your goal is to pair this type of world-class science with real human impact, there is no better place in the world to be than Genentech. Every day, our teams work to solve some of the hardest biomedical problems in the history of mankind, always with the goal of putting patients first. To do this, we become more than just scientists. We become explorers. We become pioneering drug discoverers. And as drug discoverers, we are never afraid of the unknown. In fact, we are attracted to it. Being a scientist at Genentech means living 10 years in the future and discovering transformative medicines for the people who need them.
South San Francisco, US
Size (employees)
21,601 (est)
Genentech was founded in 1976 and is headquartered in South San Francisco, US
Report incorrect company information

Genentech Office Locations

Genentech has an office in South San Francisco
Show all (1)
Report incorrect company information

Genentech Financials and Metrics

Summary Metrics

Founding Date

Show all financial metrics
Report incorrect company information

Genentech News and Updates

Human Growth Hormone Drugs Market Overview, Analysis, Major Manufacturers, Production Price, Cost, Revenue & Market Status 2018 to 2023, focusing on Top Key Vendors like: Eli Lilly and Company (US), Ferring Holding SA (Switzerland), Genentech

The Global Human Growth Hormone Drugs Market Report includes a comprehensive analysis of the present market. The report starts with the basic Human Growth Hormone Drugs Market overview and then goes into each and every detail. Posted via Industry Today. Follow us on Twitter @IndustryToday

Antibody Drug Conjugates Market to Reap Excessive Revenues by 2025

North America will continue to dominate the antibody drug conjugates market as it has high experienced professionals and better healthcare facilities. Posted via Industry Today. Follow us on Twitter @IndustryToday

The search for new Alzheimer's treatments just faced another setback — and now everything hinges on an approach that's already run into trouble

It's been a while since we've had good news in the search for new Alzheimer's drugs. On Wednesday, VTV Therapeutics, a small North Carolina biotech, said its Alzheimer's drug failed a late-stage trial.  Now, all eyes are on a set of treatments that go after the "amyloid hypothesis," an approach th…
Report incorrect company information